Stock Report

Download full stock data and analysis for free Last Updated: 09-Nov-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Zydus Lifesciences Key Ratios

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: ZYDUSLIFE | BSE: 532321

₹1,199.50

up-down-arrow ₹1.60 (0.13%)

As on 08-Nov-2026IST

Market cap

info icon

₹1,19,700 Cr

Revenue (TTM)

info icon

₹30,378 Cr

P/E Ratio

info icon

28.6

P/B Ratio

info icon

4.3

Div. Yield

info icon

0.1 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -1.34 29.17 24.02 17.40 15.06
EBIT -6.16 -24.80 -16.48 11.81 14.67
Net Profit -2.98 -28.13 -10.58 12.67 15.49
EPS -1.52 -26.01 -14.78 14.55 -2.30
Book Value -- -- 13.19 15.90 16.26
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMMar-26Mar-25
EBIT-Margin info 32.3520.6118.1821.3025.72
Net Margin info 29.8216.4813.2017.3719.47
Return on equity info 23.5417.6816.6119.6921.08
Return on Capital info 23.2920.26--21.3926.06
Return on Assets info 13.6211.708.1111.8114.77
Debt to Equity (x) info ----0.150.430.13

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
--
21.39
26.06
24.90
13.64
Peer Median
--
19.41
21.76
21.89
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

16.61

Higher than Peers by 1.42

Profit after tax / Average Net worth * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
16.61
19.69
21.08
20.52
11.60
Peer Median
15.19
18.29
17.93
16.42
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

8.11

Lower than Peers by 1.99

Profit after tax / Average Total assets * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
8.11
11.81
14.77
14.70
7.82
Peer Median
10.10
9.88
12.81
12.32
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

18.18

Lower than Peers by 0.39

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
18.18
21.30
25.72
23.20
16.53
Peer Median
18.57
18.50
18.93
21.05
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

13.20

Lower than Peers by 1.22

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
13.20
17.37
19.47
19.24
11.30
Peer Median
14.42
13.32
14.94
15.51
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

--

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
--
12.45
12.11
12.12
8.03
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

24.02

Higher than Peers by 11.89

Year on year growth in net sales

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
24.02
16.81
18.90
13.40
14.08
Peer Median
12.13
13.53
10.90
13.44
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

-16.48

Lower than Peers by 37.93

Year on year growth in operating profit (EBIT)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
-16.48
-3.27
31.82
59.16
15.74
Peer Median
21.45
20.72
15.01
23.50
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

-10.58

Lower than Peers by 33.16

Year on year growth in profit after tax

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
-10.58
8.92
20.45
91.39
-13.95
Peer Median
22.58
18.73
14.80
30.12
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

-14.78

Lower than Peers by 35.23

Year on year growth in earnings per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
-14.78
11.37
17.26
98.06
-55.80
Peer Median
20.45
18.72
14.27
29.02
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

--

--

Year on year growth in book value per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
--
13.19
20.80
13.21
3.04
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

0.15

Higher than Peers by 0.14

Total debt / Net worth

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
0.15
0.43
0.13
0.04
0.07
Peer Median
0.00
0.05
0.06
0.03
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
--
0.16
0.13
0.04
0.06
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

1.02

Lower than Peers by 0.93

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
1.02
1.27
1.89
2.14
1.81
Peer Median
1.95
1.90
1.90
2.23
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

0.64

Lower than Peers by 0.84

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
0.64
0.91
1.45
1.50
1.19
Peer Median
1.48
1.40
1.46
1.59
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

10.32

Lower than Peers by 8.78

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
10.32
16.09
32.55
60.22
20.94
Peer Median
19.10
19.02
24.96
45.29
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

14.42

Lower than Peers by 7.23

Debtors outstanding / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
14.42
19.95
17.58
26.71
25.62
Peer Median
21.65
19.75
21.77
20.10
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.59

Lower than Peers by 0.12

Sales / Average Total Assets

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
0.59
1.21
1.46
1.46
1.32
Peer Median
0.71
0.74
0.76
0.81
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
--
33.55
37.17
46.37
41.75
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
--
33.80
29.51
32.98
38.39
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
--
149.82
150.48
147.51
145.80
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
--
-82.46
-83.79
-68.16
-65.67
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

28.64

Lower than Peers by 6.50

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
28.64
17.39
19.69
26.20
25.37
Peer Median
35.13
34.31
26.81
39.85
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

4.30

Lower than Peers by 0.19

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
4.30
3.23
3.72
5.10
2.84
Peer Median
4.49
5.07
4.65
6.11
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

0.08

Lower than Peers by 0.40

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
0.08
0.11
1.24
0.30
1.22
Peer Median
0.48
0.48
0.61
0.37
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

15.14

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
15.14
10.91
12.15
17.78
12.44
Peer Median
--
26.18
27.02
34.57
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

1,19,700

Higher than Peers by 1,01,055

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
1,19,700
87,643
89,101
1,01,128
49,740
Peer Median
18,646
17,868
20,914
25,297
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...

Informed fund ideas, better judgment. Every month. Mutual Fund Insight, every month since October 2002.

Take charge. Know more. Keep more. Mutual Fund Insight helps you do all three — every month